{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T18:10:42Z","timestamp":1765995042457,"version":"3.40.5"},"reference-count":19,"publisher":"Wiley","license":[{"start":{"date-parts":[[2022,10,11]],"date-time":"2022-10-11T00:00:00Z","timestamp":1665446400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Emergency Medicine International"],"published-print":{"date-parts":[[2022,10,11]]},"abstract":"<jats:p>Objective. To compare the efficacy of febuxostat and allopurinol in the treatment of chronic kidney disease (CKD) at stages 3\u223c5 with hyperuricemia. Methods. A total of 100 patients with stage 3 to 5 CKD with hyperuricemia in our hospital from July 2018 to December 2019 were selected and divided into the control group (n\u2009=\u200950) and the experimental group (n\u2009=\u200950) according to the random number expression method, the control group on the basis of conventional treatment with allopurinol treatment, the experimental group based on conventional treatment using the febuxostat be treatment. The clinical efficacy, incidence of adverse reactions, and renal function indexes, blood urea nitrogen (BUN), serum creatinine (Scr), serum sodium (Na), serum potassium (K), and serum uric acid (UA) before and after treatment were compared between the two groups. Results. The total effective rate of the experimental group and the control group was 82.00% and 78.00%, respectively, with little difference (<jats:inline-formula>\n                     <a:math xmlns:a=\"http:\/\/www.w3.org\/1998\/Math\/MathML\" id=\"M1\">\n                        <a:mi>P<\/a:mi>\n                        <a:mo>&gt;<\/a:mo>\n                        <a:mn>0.05<\/a:mn>\n                     <\/a:math>\n                  <\/jats:inline-formula>); compared with before treatment, BUN, Scr, and UA of the two groups were decreased (<jats:inline-formula>\n                     <c:math xmlns:c=\"http:\/\/www.w3.org\/1998\/Math\/MathML\" id=\"M2\">\n                        <c:mi>P<\/c:mi>\n                        <c:mo>&lt;<\/c:mo>\n                        <c:mn>0.05<\/c:mn>\n                     <\/c:math>\n                  <\/jats:inline-formula>); and the degree of decline in the experimental group was significantly greater than that in the control group (<jats:inline-formula>\n                     <e:math xmlns:e=\"http:\/\/www.w3.org\/1998\/Math\/MathML\" id=\"M3\">\n                        <e:mi>P<\/e:mi>\n                        <e:mo>&lt;<\/e:mo>\n                        <e:mn>0.05<\/e:mn>\n                     <\/e:math>\n                  <\/jats:inline-formula>); the incidence of adverse reactions in the control group was 22.00%, which was significantly higher than that in the experimental group (10.00%) (<jats:inline-formula>\n                     <g:math xmlns:g=\"http:\/\/www.w3.org\/1998\/Math\/MathML\" id=\"M4\">\n                        <g:mi>P<\/g:mi>\n                        <g:mo>&lt;<\/g:mo>\n                        <g:mn>0.05<\/g:mn>\n                     <\/g:math>\n                  <\/jats:inline-formula>). Conclusion. Compared with allopurinol, febuxostat can improve renal function, reduce UA levels, and reduce the occurrence of complications, with high safety, which is worthy of further clinical promotion.<\/jats:p>","DOI":"10.1155\/2022\/1177946","type":"journal-article","created":{"date-parts":[[2022,10,12]],"date-time":"2022-10-12T02:35:27Z","timestamp":1665542127000},"page":"1-4","source":"Crossref","is-referenced-by-count":3,"title":["Comparison of Febuxostat and Allopurinol in the Treatment of Patients with Chronic Kidney Disease Stage 3\u223c5 with Hyperuricemia"],"prefix":"10.1155","volume":"2022","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1580-3098","authenticated-orcid":true,"given":"Zhimin","family":"Liao","sequence":"first","affiliation":[{"name":"Department of Nephrology, The Second People\u2019s Hospital of Liangshan Yi Autonomous Prefecture, Xichang, Sichuan 615000, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Xu","sequence":"additional","affiliation":[{"name":"The Second People\u2019s Hospital of Liangshan Yi Autonomous Prefecture, Xichang, Sichuan 615000, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo","family":"Wan","sequence":"additional","affiliation":[{"name":"Department of Nephrology, The Second People\u2019s Hospital of Liangshan Yi Autonomous Prefecture, Xichang, Sichuan 615000, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liping","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Nephrology, The Second People\u2019s Hospital of Liangshan Yi Autonomous Prefecture, Xichang, Sichuan 615000, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chengzhi","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Nephrology, The Second People\u2019s Hospital of Liangshan Yi Autonomous Prefecture, Xichang, Sichuan 615000, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gang","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Nephrology, The Second People\u2019s Hospital of Liangshan Yi Autonomous Prefecture, Xichang, Sichuan 615000, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3313-6225","authenticated-orcid":true,"given":"Rui","family":"Xie","sequence":"additional","affiliation":[{"name":"Department of Nephrology, The Second People\u2019s Hospital of Liangshan Yi Autonomous Prefecture, Xichang, Sichuan 615000, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","reference":[{"doi-asserted-by":"publisher","key":"1","DOI":"10.1097\/bco.0b013e318298452e"},{"issue":"41","key":"2","first-page":"526","article-title":"Treatment of chronic kidney disease with hyperuricemia with febuxostat and allopurinol","volume":"31","author":"L. Min","year":"2019","journal-title":"China Continuing Medical Education"},{"doi-asserted-by":"publisher","key":"3","DOI":"10.1097\/brs.0b013e318193ca06"},{"issue":"41","key":"4","first-page":"623","article-title":"The urate-lowering efficacy and safety of febuxostat versus allopurinol in Chinese patients with asymptomatic hyperuricemia and with chronic kidney disease stages 3\u20135","volume":"36","author":"L. Xuemei","year":"2018","journal-title":"Clinical and Experimental Nephrology"},{"doi-asserted-by":"publisher","key":"5","DOI":"10.1016\/j.jvir.2011.08.021"},{"doi-asserted-by":"publisher","key":"6","DOI":"10.3171\/2010.3.spine09364"},{"issue":"41","key":"7","first-page":"235","article-title":"Comparison of renoprotective effects of febuxostat and allopurinol in hyperuricemic patients with chronic kidney disease","volume":"30","author":"J. W. Lee","year":"2019","journal-title":"International Urology and Nephrology"},{"doi-asserted-by":"publisher","key":"8","DOI":"10.1016\/j.spinee.2014.08.305"},{"doi-asserted-by":"publisher","key":"9","DOI":"10.31616\/asj.2018.0297.r1"},{"issue":"15","key":"10","first-page":"512","article-title":"Efficacy and safety of febuxostat for treating hyperuricemia in patients with chronic kidney disease and in renal transplant recipients: a systematic review and meta-analysis","volume":"34","author":"L. Xuzhong","year":"2018","journal-title":"Experimental and Therapeutic Medicine"},{"doi-asserted-by":"publisher","key":"11","DOI":"10.3340\/jkns.2015.57.5.367"},{"issue":"1-4","key":"12","first-page":"525","article-title":"Die Stapesrevisionsoperation: eine retrospektive und klinische studie","volume":"220","author":"J. S. Friedrich","year":"2003","journal-title":"Zeitschrift F\u00fcr Kristallographie\u2014New Crystal Structures"},{"doi-asserted-by":"publisher","key":"13","DOI":"10.1038\/s41419-018-0600-3"},{"doi-asserted-by":"publisher","key":"14","DOI":"10.31616\/asj.2018.12.5.935"},{"issue":"51","key":"15","first-page":"412","article-title":"Effectiveness of febuxostat in patients with allopurinol-refractory hyperuricemic chronic kidney disease","volume":"31","author":"C. H. Kwak","year":"2018","journal-title":"International Journal of Clinical Pharmacology and Therapeutics"},{"issue":"7","key":"16","first-page":"101","article-title":"Pathomechanism of intravertebral clefts in osteoporotic compression fractures of the spine","volume":"16","author":"Y. C. Kim","year":"2013","journal-title":"The Spine Journal"},{"issue":"4","key":"17","first-page":"93","article-title":"Should the results of the HOPE study affect nephrological practice?","volume":"15","author":"J. F. Mann","year":"2000","journal-title":"Nephrology, Dialysis, Transplantation: Official Publication of the European Dialysis and Transplant Association\u2014European Renal Association"},{"doi-asserted-by":"publisher","key":"18","DOI":"10.1007\/s11255-018-2051-2"},{"issue":"51","key":"19","first-page":"432","article-title":"Effect of febuxostat on renal protection in chronic kidney disease patients complicated with hyperuricemia: a randomized, controlled study","volume":"15","author":"T. Zhao","year":"2019","journal-title":"Journal of Fujian Medical University"}],"container-title":["Emergency Medicine International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/downloads.hindawi.com\/journals\/emi\/2022\/1177946.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/downloads.hindawi.com\/journals\/emi\/2022\/1177946.xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/downloads.hindawi.com\/journals\/emi\/2022\/1177946.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,12]],"date-time":"2022-10-12T02:35:45Z","timestamp":1665542145000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.hindawi.com\/journals\/emi\/2022\/1177946\/"}},"subtitle":[],"editor":[{"given":"Weiguo","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2022,10,11]]},"references-count":19,"alternative-id":["1177946","1177946"],"URL":"https:\/\/doi.org\/10.1155\/2022\/1177946","relation":{},"ISSN":["2090-2859","2090-2840"],"issn-type":[{"type":"electronic","value":"2090-2859"},{"type":"print","value":"2090-2840"}],"subject":[],"published":{"date-parts":[[2022,10,11]]}}}